Development and validation of an automated microfluidic perfusion platform for parallelized screening of compounds in vitro.
automated screening
microfluidics
neurotransmitter
release assay
serotonin
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
28
07
2023
received:
06
06
2023
accepted:
29
08
2023
medline:
9
11
2023
pubmed:
2
9
2023
entrez:
2
9
2023
Statut:
ppublish
Résumé
Monoamine transporters are of great interest for their role in the physiological activity of the body and their link to mental and behavioural disorders. Currently, static well-plate assays or manual perfusion systems are used to characterize the interaction of psychostimulants, antidepressants and drugs of abuse with the transporters but still suffer from significant drawbacks caused by lack of automation, for example, low reproducibility, non-comparability of results. An automated microfluidic platform was developed to address the need for more standardized procedures for cell-based assays. An automated system was used to control and drive the simultaneous perfusion of 12 channels on a microfluidic chip, establishing a more standardized protocol to perform release assays to study monoamine transporter-mediated substrate efflux. D-Amphetamine, GBR12909 (norepinephrine transporter) and p-chloroamphetamine, paroxetine (serotonin transporter) were used as control compounds to validate the system. The platform was able to produce the expected releasing (D-Amphetamine, p-chloroamphetamine) or inhibiting (GBR12909, paroxetine) profiles for the two transporters. The reduction of manual operation and introduction of automated flow control enabled the implementation of stronger standardized protocols and the possibility of obtaining higher throughput by increasing parallelization.
Substances chimiques
p-Chloroamphetamine
64-12-0
Paroxetine
41VRH5220H
Membrane Transport Proteins
0
Dextroamphetamine
TZ47U051FI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-547Subventions
Organisme : Austrian Science Fund FWF
ID : DOC 33
Pays : Austria
Informations de copyright
© 2023 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Références
J Neurochem. 1998 Sep;71(3):1289-97
pubmed: 9721755
Science. 2001 Sep 28;293(5539):2465-70
pubmed: 11577238
Drug Alcohol Depend. 2015 Feb 1;147:1-19
pubmed: 25548026
Basic Clin Pharmacol Toxicol. 2021 Jan;128(1):4-8
pubmed: 32955760
Neurochem Int. 2014 Jul;73:32-41
pubmed: 24296074
Front Bioeng Biotechnol. 2020 Nov 13;8:589074
pubmed: 33282849
J Biol Chem. 2002 Sep 20;277(38):34846-52
pubmed: 12105193
Front Pharmacol. 2021 Apr 09;12:654061
pubmed: 33897439
Arch Pathol Lab Med. 2014 Dec;138(12):1578-82
pubmed: 25427039
Lab Chip. 2007 Jun;7(6):740-5
pubmed: 17538716
Curr Top Behav Neurosci. 2017;32:333-350
pubmed: 28025810
Trends Pharmacol Sci. 2020 Jul;41(7):446-463
pubmed: 32471654
Basic Clin Pharmacol Toxicol. 2023 Nov;133(5):535-547
pubmed: 37658634
J Neurochem. 1989 Feb;52(2):331-41
pubmed: 2562986
Mol Pharmacol. 1995 Feb;47(2):368-73
pubmed: 7870046
Br J Pharmacol. 2016 Sep;173(17):2657-68
pubmed: 27391165
J Neurosci. 1997 Feb 1;17(3):960-74
pubmed: 8994051
Commun Biol. 2022 Jun 10;5(1):578
pubmed: 35689020
J Biol Chem. 2023 Aug;299(8):105063
pubmed: 37468107
Lab Chip. 2021 Aug 7;21(15):2857-2868
pubmed: 34251386
Br J Pharmacol. 1997 May;121(2):205-12
pubmed: 9154329
Br J Pharmacol. 2013 Jan;168(2):458-70
pubmed: 22897747
Front Pharmacol. 2020 May 19;11:673
pubmed: 32508638
Neuroscience. 1991;41(1):1-24
pubmed: 1676137
Biochim Biophys Acta. 1990 May 7;1031(2):225-46
pubmed: 2160275
Commun Biol. 2022 Nov 17;5(1):1259
pubmed: 36396757
J Biol Chem. 2004 Nov 26;279(48):49671-9
pubmed: 15358780
Eur J Pharmacol. 2013 Jan 5;698(1-3):1-5
pubmed: 23178799
Neuropharmacology. 2005 Nov;49(6):811-9
pubmed: 16185723
J Biol Chem. 2002 Jun 14;277(24):21505-13
pubmed: 11940571
J Neurochem. 2010 Jan;112(2):340-55
pubmed: 19891736
J Pharmacol Exp Ther. 2000 Jun;293(3):870-8
pubmed: 10869387
Trends Pharmacol Sci. 2015 Jan;36(1):41-50
pubmed: 25542076
J Pharmacol Exp Ther. 2013 Jul;346(1):2-10
pubmed: 23568856
J Neurochem. 2011 Aug;118(4):475-89
pubmed: 21644994
Trends Biotechnol. 1998 Sep;16(9):373-8
pubmed: 9744112
Curr Opin Biotechnol. 2000 Feb;11(1):47-53
pubmed: 10679349
Small. 2022 Dec;18(48):e2205001
pubmed: 36310131
J Pharmacol Exp Ther. 1988 Jun;245(3):944-9
pubmed: 2838608
Mol Pharmacol. 2016 Jan;89(1):165-75
pubmed: 26519222
Nat Commun. 2017 Nov 20;8(1):1620
pubmed: 29158473
J Biomech Eng. 2022 Feb 1;144(2):
pubmed: 34254640
Psychopharmacology (Berl). 2007 Jan;189(4):489-503
pubmed: 16220332
Neuropsychopharmacology. 2012 Apr;37(5):1192-203
pubmed: 22169943
Nature. 2006 Jul 27;442(7101):368-73
pubmed: 16871203
Lab Chip. 2012 May 8;12(11):2037-45
pubmed: 22508372
Trends Pharmacol Sci. 1988 Aug;9(8):274-6
pubmed: 2907952
Trends Neurosci. 1993 Oct;16(10):415-9
pubmed: 7504357
Elife. 2021 Jun 01;10:
pubmed: 34061030
Neuropsychopharmacology. 2015 May;40(6):1321-31
pubmed: 25502630
Naunyn Schmiedebergs Arch Pharmacol. 1977 Sep;299(2):163-5
pubmed: 909611
Neuropharmacology. 2021 Jun 1;190:108570
pubmed: 33864800
Front Neurosci. 2020 Jan 29;14:9
pubmed: 32063828
Pharmacol Rev. 2011 Sep;63(3):585-640
pubmed: 21752877
Mol Pharmacol. 1994 Feb;45(2):312-6
pubmed: 7906856
Lancet Neurol. 2011 Aug;10(8):721-33
pubmed: 21777827
Mol Pharmacol. 2019 Mar;95(3):303-312
pubmed: 30567955
J Biomol Screen. 2003 Oct;8(5):522-32
pubmed: 14567779
Eur J Pharmacol. 2007 Mar 22;559(2-3):132-7
pubmed: 17223101
Anal Methods. 2015 Feb 7;7(3):884-893
pubmed: 25663849
Mol Pharmacol. 1995 Mar;47(3):544-50
pubmed: 7700252